Class ITerminatedD-1337-2022
Drug recall · July 27, 2022
Launch Sequence Euphoria Capsules recall
Why: Marketed Without An Approved NDA/ANDA: Product found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864.
- Lots / codes
Lot # 2022104, Exp. Date 04/2025
- Quantity
- 1000 10-count tins
- Company
- Loud Muscle Science, Hauppauge, NY
- Distribution
- The product was distributed nationwide in the USA and Canada.
- Initiated
- June 27, 2022 · Voluntary: Firm initiated
- Classified
- August 15, 2022
- Reported
- July 27, 2022
- Ended
- February 8, 2023
- How notified
- Press Release
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Class ITerminatedJul 27, 2022Launch Sequence CapsulesLoud Muscle Science · D-1336-2022Class ITerminatedJul 27, 2022Launch Sequence Aphrodisia CapsulesLoud Muscle Science · D-1338-2022Class IITerminatedJul 27, 2022Launch Sequence CapsulesLoud Muscle Science · D-1339-2022Class IITerminatedJul 27, 2022Launch Sequence Euphoria CapsulesLoud Muscle Science · D-1340-2022Class IITerminatedJul 27, 2022Launch Sequence Aphrodisia CapsulesLoud Muscle Science · D-1341-2022
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.